Pre-Open Stock Movers 03/01: (CTIC) (TGT) (DDD) Higher; (GDRX) (VRM) (AMBA) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Baidu (BIDU) PT Raised to $200 at Susquehanna
March 3, 2022 6:30 AM ESTSusquehanna analyst Shyam Patel raised the price target on Baidu (NASDAQ: BIDU) to $200.00 (from $175.00) while maintaining a Positive rating following solid Q4 given the macro backdrop.
The analyst commented, "Although BIDU continues to be cautious around the pandemic and macro situation in... More
Target (TGT) PT Lowered to $252 at Jefferies
March 2, 2022 7:58 AM ESTJefferies analyst Stephanie Wissink lowered the price target on Target (NYSE: TGT) to $252.00 (from $260.00) while maintaining a Hold rating following results.
The analyst commented, "Q4 comps were light at +9% driven fully by traffic but margins were better, leading to Q4 EPS beat.... More
Target (TGT) PT Raised to $290 at JPMorgan, 'More Upside Expected in Near Term'
March 1, 2022 5:33 PM ESTJPMorgan analyst Christopher Horvers raised the price target on Target (NYSE: TGT) to $290.00 (from $262.00) while maintaining a Overweight rating.
The analyst comments "TGT is a core long-term holding given its ability to compete in the new world of omni-channel retailing and its... More
CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval
March 1, 2022 10:13 AM ESTBrookline Capital Markets analyst Leah Rush Cann raised the price target on CTI BioPharma (NASDAQ: CTIC) to $12.00 (from $7.20) while maintaining a Buy rating following FDA approval for Pacritinib (Vonjo) in Myelofibrosis.
The analyst commented, "The timing of this FDA-approval is as expected and the prescribing label, with no black box warning and an... More
